
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
K173171
B. Purpose for Submission:
To obtain a substantial equivalence determination for the FilmArray RP2/RP2plus Control
Panel, P/N M315
C. Measurand:
Multi-analyte quality control materials
D. Type of Test:
FilmArray RP2/RP2plus Control Panel is intended for in vitro diagnostic use as external
assayed quality control materials to monitor the qualitative amplification, detection and
identification steps of the laboratory nucleic acid test, FilmArray RP2/RP2plus assay on the
FilmArray 2.0 instrument or FilmArray Torch system, which detects respiratory pathogens:
Adenovirus, Coronavirus, Human Metapneumovirus, Human Rhinovirus/ Enterovirus,
Influenza A, Influenza A subtype H1, Influenza A subtype H1-2009, Influenza A subtype
H3, Influenza B, Middle East Respiratory Syndrome Coronavirus, Parainfluenza Virus,
Respiratory Syncytial Virus, Bordetella parapertussis, Bordetella pertussis, Chlamydia
pneumoniae, and Mycoplasma pneumoniae.
E. Applicant:
Maine Molecular Quality Controls, Inc. (MMQCI)
F. Proprietary and Established Names:
FilmArray RP2/RP2plus Control Panel, P/N M315
G. Regulatory Information:
1. Regulation section:
21 CFR 866.3920, Assayed quality control material for clinical microbiology assays
2. Classification:
Class II (Special Controls)
1

--- Page 2 ---
3. Product code:
PMN
4. Panel:
83- Microbiology
H. Indication(s) for use:
1. Indications for use(s):
FilmArray RP2/RP2plus Control Panel is intended for use as an external positive and
negative assayed quality control to monitor performance of in vitro laboratory nucleic
acid testing procedures for the qualitative detection of Adenovirus, Coronavirus, Human
Metapneumovirus, Human Rhinovirus/ Enterovirus, Influenza A, Influenza A subtype
H1, Influenza A subtype H1-2009, Influenza A subtype H3, Influenza B, Middle East
Respiratory Syndrome Coronavirus, Parainfluenza Virus, Respiratory Syncytial Virus,
Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma
pneumoniae by BioFire's FilmArray RP2 and RP2plus assays on the FilmArray 2.0 or the
FilmArray Torch Systems. FilmArray RP2/RP2plus Control Panel is composed of
synthetic RNA designed for and intended to be used solely with the FilmArray RP2 and
RP2plus assays. This product is not intended to replace manufacturer internal controls
provided with the test system.
2. Special conditions for use statement(s):
For in vitro diagnostic use only
For prescription use only
3. Special instrument requirements:
FilmArray RP2/RP2plus Control Panel was evaluated on FilmArray 2.0 instrument.
I. Device Description:
FilmArray RP2/RP2plus Control Panel is a quality control panel consisting of two controls:
FilmArray RP2/RP2plus Positive Control and FilmArray RP2/RP2plus Negative Control.
The Positive Control contains non-infectious surrogate control material; a solution of
synthetic RNA transcripts in buffers, stabilizers and preservatives. The RNA carries
segments of all respiratory pathogens detected by the FilmArray RP2 and RP2plus assays
(see Table below) on the FilmArray 2.0 or FilmArray Torch systems. The RNA in the
Negative Control is non-specific RNA in buffers, stabilizers and preservatives. Each liquid
control of FilmArray RP2/RP2plus Control Panel M265 is processed separately according to
FilmArray RP2 and RP2plus assays manufacturer’s Instructions for Use for patient samples
2

--- Page 3 ---
(nasopharyngeal swabs) obtained from individuals suspected of respiratory tract infection
and placed in Viral Transport Media (VTM)).
The FilmArray RP2/RP2plus Positive Control is prepared nucleic acid concentrations of 5X-
10X LoD for each of the organisms detected by the FilmArray RP2/RP2plus assay.
Respiratory pathogens detected by FilmArray RP2 and RP2plus assay
Adenovirus Parainfluenza Virus 1
Coronavirus 229E Parainfluenza Virus 2
Coronavirus HKU1 Parainfluenza Virus 3
Coronavirus NL63 Parainfluenza Virus 4
Coronavirus OC43 Respiratory Syncytial Virus
Human Metapneumovirus Bordetella parapertussis (IS001)
Human Rhinovirus/ Enterovirus Bordetella pertussis (ptxP)
Influenza A, subtypes H1, H1-2009, H3 Chlamydia pneumoniae
Influenza B Mycoplasma pneumoniae
Middle East Respiratory Syndrome Coronavirus*
*Detected by FilmArray RP2plus assay only.
J. Substantial Equivalence Information:
1. Predicate device name(s):
FilmArray RP EZ Control Panel M265, Maine Molecular Quality Controls, Inc.
2. Predicate 510(k) number(s):
K161573
3. Comparison with predicate:
There are no differences between the intended uses of the predicate (K161573) and the
new device which raise new questions of safety and effectiveness.
3

[Table 1 on page 3]
Respiratory pathogens detected by FilmArray RP2 and RP2plus assay	
Adenovirus	Parainfluenza Virus 1
Coronavirus 229E	Parainfluenza Virus 2
Coronavirus HKU1	Parainfluenza Virus 3
Coronavirus NL63	Parainfluenza Virus 4
Coronavirus OC43	Respiratory Syncytial Virus
Human Metapneumovirus	Bordetella parapertussis (IS001)
Human Rhinovirus/ Enterovirus	Bordetella pertussis (ptxP)
Influenza A, subtypes H1, H1-2009, H3	Chlamydia pneumoniae
Influenza B	Mycoplasma pneumoniae
Middle East Respiratory Syndrome Coronavirus*	

--- Page 4 ---
Similarities
Item FilmArray RP2/RP2plus FilmArray RP EZ Control
Control Panel M315 Panel M265 (K161573)
(K173171)
Intended Use FilmArray RP2/RP2plus Control FilmArray RP EZ Control Panel M265
Panel is intended for use as an is intended for use as external positive
external positive and negative and negative, surrogate assayed quality
assayed quality control to monitor control materials to monitor the
performance of in vitro laboratory performance of in vitro laboratory
nucleic acid testing procedures for nucleic acid testing procedures for the
the qualitative detection of qualitative detection of Adenovirus,
Adenovirus, Coronavirus, Human Coronavirus, Human
Metapneumovirus, Human Metapneumovirus, Human Rhinovirus/
Rhinovirus/ Enterovirus, Influenza Enterovirus, Influenza A, Influenza A
A, Influenza A subtype H1, subtype H1, Influenza A subtype H3,
Influenza A subtype H1-2009, Influenza A subtype H1-2009,
Influenza A subtype H3, Influenza Influenza B, Parainfluenza Virus,
B, Middle East Respiratory Respiratory Syncytial Virus, Bordetella
Syndrome Coronavirus, pertussis, Chlamydophila pneumoniae,
Parainfluenza Virus, Respiratory and Mycoplasma pneumonia on the
Syncytial Virus, Bordetella FilmArray RP EZ assay performed on
parapertussis, Bordetella pertussis, the FilmArray systems. The control
Chlamydia pneumoniae, and panel also contains a negative control.
Mycoplasma pneumoniae by This product is not intended to replace
BioFire's FilmArray RP2 and manufacturer controls provided with
RP2plus assays on the FilmArray the device.
2.0 or the FilmArray Torch
Systems. FilmArray RP2/RP2plus
Control Panel is composed of
synthetic RNA designed for and
intended to be used solely with the
FilmArray RP2 and RP2plus
assays. This product is not
intended to replace manufacturer
internal controls provided with the
test system.
Format Ready-to-Use Liquid Same
Directions Process like patient Same
for Use sample Same
Composition Synthetic RNA transcripts Same
Assay Steps Reverse transcription, Same
Monitored amplification, detection,
identification
Number of Multiple Same
Targets
4

[Table 1 on page 4]
Similarities		
Item	FilmArray RP2/RP2plus
Control Panel M315	FilmArray RP EZ Control
Panel M265 (K161573)
Intended Use	(K173171)
FilmArray RP2/RP2plus Control
Panel is intended for use as an
external positive and negative
assayed quality control to monitor
performance of in vitro laboratory
nucleic acid testing procedures for
the qualitative detection of
Adenovirus, Coronavirus, Human
Metapneumovirus, Human
Rhinovirus/ Enterovirus, Influenza
A, Influenza A subtype H1,
Influenza A subtype H1-2009,
Influenza A subtype H3, Influenza
B, Middle East Respiratory
Syndrome Coronavirus,
Parainfluenza Virus, Respiratory
Syncytial Virus, Bordetella
parapertussis, Bordetella pertussis,
Chlamydia pneumoniae, and
Mycoplasma pneumoniae by
BioFire's FilmArray RP2 and
RP2plus assays on the FilmArray
2.0 or the FilmArray Torch
Systems. FilmArray RP2/RP2plus
Control Panel is composed of
synthetic RNA designed for and
intended to be used solely with the
FilmArray RP2 and RP2plus
assays. This product is not
intended to replace manufacturer
internal controls provided with the
test system.	FilmArray RP EZ Control Panel M265
is intended for use as external positive
and negative, surrogate assayed quality
control materials to monitor the
performance of in vitro laboratory
nucleic acid testing procedures for the
qualitative detection of Adenovirus,
Coronavirus, Human
Metapneumovirus, Human Rhinovirus/
Enterovirus, Influenza A, Influenza A
subtype H1, Influenza A subtype H3,
Influenza A subtype H1-2009,
Influenza B, Parainfluenza Virus,
Respiratory Syncytial Virus, Bordetella
pertussis, Chlamydophila pneumoniae,
and Mycoplasma pneumonia on the
FilmArray RP EZ assay performed on
the FilmArray systems. The control
panel also contains a negative control.
This product is not intended to replace
manufacturer controls provided with
the device.
Format	Ready-to-Use Liquid	Same
Directions
for Use	Process like patient
sample Same	Same
Composition	Synthetic RNA transcripts	Same
Assay Steps
Monitored	Reverse transcription,
amplification, detection,
identification	Same
Number of
Targets	Multiple	Same

--- Page 5 ---
K. Standard/Guidance Document Referenced (if applicable):
None were referenced
L. Test Principle:
Not applicable
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Reproducibility:
A multi-site reproducibility study was performed with the FilmArray RP2/RP2plus
Control Panel on FilmArray instrument 2.0. Testing consisted of three positive and
three negative controls run per day, and spanned a period of 10 days (total of 60
control runs per site). Multiple operators participated in testing at each of the three
locations. Three lots each of external control material and three lots of FilmArray
RP2 pouches were tested across all sites. A total of 180 external controls were tested
(90 positive and 90 negative). The results are shown in the tables below:
FilmArray RP2/RP2plus Control Panel Summary of External Reproducibility Test Results
All Sites All Sites
SITE
Site #1 Site #2 Site #3
Category
#expected % #expected % #expected % Overall 95%
results/# Agreement results/# Agreement results/# Agreement Percent Confidence
tested1 with tested with tested with Agreement Interval
Expected Expected Expected
Result 1 Result 1 Result 1
FilmArray 30/30 100% 30/30 100% 30/30 100% 100% 95.9% to
RP2/RP2 90/90 100%
plus
Positive
Control
FilmArray 30/30 100% 30/30 100% 30/30 100% 100% 95.9% to
RP2/RP2 90/90 100%
plus
Negative
Control
1 Expected result for the FilmArray RP2/RP2plus Positive Control is positive. Expected result for the FilmArray
RP2/RP2plus Negative Control is negative
5

[Table 1 on page 5]
	FilmArray RP2/RP2plus Control Panel Summary of External Reproducibility Test Results									
Category		SITE						All Sites	All Sites	
								Overall
Percent
Agreement	95%
Confidence
Interval	
		Site #1		Site #2		Site #3				
		#expected
results/#
tested1	%
Agreement
with
Expected
Result 1	#expected
results/#
tested	%
Agreement
with
Expected
Result 1	#expected
results/#
tested	%
Agreement
with
Expected
Result 1			
FilmArray
RP2/RP2
plus
Positive
Control		30/30	100%	30/30	100%	30/30	100%	100%
90/90	95.9% to
100%	
FilmArray
RP2/RP2
plus
Negative
Control		30/30	100%	30/30	100%	30/30	100%	100%
90/90	95.9% to
100%	

--- Page 6 ---
Crossing Point (Cp) Data for FilmArray RP2/RP2plus Panel External Reproducibility Study
All External Sites
Respiratory Site 1 Site 2 Site 3
Pathogen
Ave Cp SD Ave Cp SD Ave Cp SD Ave Cp SD
Analyte
Adeno2 19.9 2.0 18.8 2.0 19.5 1.6 19.4 1.9
Adeno3 17.5 1.5 17.5 1.9 18.4 1.3 17.8 1.6
Adeno6 15.4 1.7 15.2 1.6 16.0 1.4 15.6 1.6
Adeno7.1 16.1 1.9 15.9 1.4 16.0 1.9 16.0 1.7
Adeno8 13.8 1.4 13.9 1.2 14.0 1.2 13.9 1.3
IS1001 18.1 1.2 18.2 1.4 18.6 0.9 18.3 1.2
ptxP 14.6 1.4 14.6 1.4 15.2 1.2 14.8 1.4
Cpne 15.6 0.9 15.7 1.1 15.5 0.7 15.6 0.9
CoV-229E 16.1 1.2 16.2 1.1 16.1 0.9 16.1 1.0
CoV-HKU1 17.6 1.3 17.6 1.2 17.8 1.0 17.6 1.2
CoV-NL63 17.3 2.2 17.2 1.3 17.1 1.4 17.2 1.7
CoV-OC43-2 19.6 2.6 19.1 1.5 19.1 1.9 19.2 2.0
CoV-OC43 16.3 0.9 16.5 1.0 16.5 0.9 16.4 1.0
hMPV 17.7 2.5 16.7 1.6 16.8 2.1 17.1 2.1
HRV/EV 16.4 0.8 16.4 1.1 16.6 0.8 16.5 0.9
FluA-H1-2 19.3 1.8 19.1 1.1 19.2 1.7 19.2 1.5
FluA-H1-2009 19.0 1.2 18.8 1.3 19.2 1.5 19.0 1.4
FluA-H3 16.0 0.7 16.0 1.4 16.1 0.6 16.0 1.0
FluA-pan1 15.3 0.8 15.5 1.1 15.4 0.6 15.4 0.9
FluA-pan2 16.8 1.9 16.5 1.2 16.3 1.4 16.5 1.5
FluB 15.8 1.1 15.9 1.1 15.7 0.7 15.8 1.0
MERS1 19.2 2.2 18.9 1.4 19.3 1.8 19.1 1.8
MERS2 17.2 1.4 17.3 1.4 17.6 1.0 17.4 1.3
Mpne 16.5 1.6 16.5 1.2 16.5 1.3 16.5 1.4
PIV1 16.4 2.6 15.7 1.6 15.8 1.6 16.0 2.0
PIV2 19.2 1.8 19.0 1.3 19.1 1.7 19.1 1.6
PIV3 17.6 1.3 17.5 1.1 17.4 1.1 17.5 1.2
PIV4 19.1 1.6 18.7 1.3 18.8 1.3 18.9 1.4
RSV 15.4 1.2 15.4 1.0 15.3 0.8 15.4 1.0
The results suggest that there are no significant differences between different users
and different sites on different days. External reproducibility studies for the
FilmArray RP2/RP2plus Panel are acceptable.
6

[Table 1 on page 6]
Crossing Point (Cp) Data for FilmArray RP2/RP2plus Panel External Reproducibility Study								
								
Respiratory
Pathogen
Analyte	Site 1		Site 2		Site 3		All External Sites	
	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD	Ave Cp	SD
Adeno2	19.9	2.0	18.8	2.0	19.5	1.6	19.4	1.9
Adeno3	17.5	1.5	17.5	1.9	18.4	1.3	17.8	1.6
Adeno6	15.4	1.7	15.2	1.6	16.0	1.4	15.6	1.6
Adeno7.1	16.1	1.9	15.9	1.4	16.0	1.9	16.0	1.7
Adeno8	13.8	1.4	13.9	1.2	14.0	1.2	13.9	1.3
IS1001	18.1	1.2	18.2	1.4	18.6	0.9	18.3	1.2
ptxP	14.6	1.4	14.6	1.4	15.2	1.2	14.8	1.4
Cpne	15.6	0.9	15.7	1.1	15.5	0.7	15.6	0.9
CoV-229E	16.1	1.2	16.2	1.1	16.1	0.9	16.1	1.0
CoV-HKU1	17.6	1.3	17.6	1.2	17.8	1.0	17.6	1.2
CoV-NL63	17.3	2.2	17.2	1.3	17.1	1.4	17.2	1.7
CoV-OC43-2	19.6	2.6	19.1	1.5	19.1	1.9	19.2	2.0
CoV-OC43	16.3	0.9	16.5	1.0	16.5	0.9	16.4	1.0
hMPV	17.7	2.5	16.7	1.6	16.8	2.1	17.1	2.1
HRV/EV	16.4	0.8	16.4	1.1	16.6	0.8	16.5	0.9
FluA-H1-2	19.3	1.8	19.1	1.1	19.2	1.7	19.2	1.5
FluA-H1-2009	19.0	1.2	18.8	1.3	19.2	1.5	19.0	1.4
FluA-H3	16.0	0.7	16.0	1.4	16.1	0.6	16.0	1.0
FluA-pan1	15.3	0.8	15.5	1.1	15.4	0.6	15.4	0.9
FluA-pan2	16.8	1.9	16.5	1.2	16.3	1.4	16.5	1.5
FluB	15.8	1.1	15.9	1.1	15.7	0.7	15.8	1.0
MERS1	19.2	2.2	18.9	1.4	19.3	1.8	19.1	1.8
MERS2	17.2	1.4	17.3	1.4	17.6	1.0	17.4	1.3
Mpne	16.5	1.6	16.5	1.2	16.5	1.3	16.5	1.4
PIV1	16.4	2.6	15.7	1.6	15.8	1.6	16.0	2.0
PIV2	19.2	1.8	19.0	1.3	19.1	1.7	19.1	1.6
PIV3	17.6	1.3	17.5	1.1	17.4	1.1	17.5	1.2
PIV4	19.1	1.6	18.7	1.3	18.8	1.3	18.9	1.4
RSV	15.4	1.2	15.4	1.0	15.3	0.8	15.4	1.0

--- Page 7 ---
b. Precision:
An internal precision study for the FilmArray RP2/RP2plus was conducted over
twenty days by testing three FilmArray RP2/RP2plus Control Panel lots with four
FilmArray RP2/RP2plus assay lots performed by four operators using two FilmArray
2.0 instruments. The results are shown in the table below:
FilmArray RP2/RP2plus Control Panel Summary of Internal Precision Test Results
Category #expected results/ Overall Percent 95% Confidence Interval
#tested1 Agreement
FilmArray 60/60 100% 94% to 100%
RP2/RP2plus
Positive Control
FilmArray 60/61 98.4% 91.3% to 99.7%
RP2/RP2plus
Negative Control
1Expected result for the FilmArray RP2/RP2plus Positive Control is positive. Expected result for the FilmArray RP2/RP2plus
Negative Control is negative.
7

[Table 1 on page 7]
FilmArray RP2/RP2plus Control Panel Summary of Internal Precision Test Results			
Category	#expected results/
#tested1	Overall Percent
Agreement	95% Confidence Interval
FilmArray
RP2/RP2plus
Positive Control	60/60	100%	94% to 100%
FilmArray
RP2/RP2plus
Negative Control	60/61	98.4%	91.3% to 99.7%

--- Page 8 ---
Crossing Point (Cp) data for FilmArray RP2/RP2plus Control Panel Internal Precision Study
Respiratory C11MAY17 G12JUN17 B21JUN17 All Lots All Lots All Lots
Pathogen Mean Mean Mean
SD SD SD Mean Cp SD %CV
Analyte Cp Cp Cp
Adeno2 19.0 1.4 19.2 1.2 18.9 1.4 18.9 1.3 7.0%
Adeno3 17.1 1.5 17.6 1.5 17.6 1.3 17.5 1.5 8.4%
Adeno6 15.1 1.3 15.4 1.4 15.5 1.2 15.4 1.4 8.8%
Adeno7.1 15.5 1.3 15.5 1.3 16.0 1.1 15.7 1.3 8.3%
Adeno8 13.5 0.8 13.7 1.1 14.1 0.8 13.8 0.9 6.7%
IS1001 18.1 1.0 18.3 1.0 18.2 1.0 18.2 1.0 5.5%
ptxP 14.5 1.1 15.0 1.1 15.0 1.0 14.9 1.1 7.5%
Cpne 15.3 0.5 15.4 0.6 15.2 0.5 15.3 0.5 3.4%
CoV-229E 16.3 0.8 16.7 1.0 16.5 0.7 16.6 0.8 5.1%
CoV-HKU1 17.5 0.6 17.5 0.8 17.7 0.6 17.6 0.7 3.9%
CoV-NL63 17.0 0.9 17.1 1.0 17.2 0.8 17.1 0.9 5.1%
CoV-OC43-2 20.3 1.5 20.5 1.4 20.9 1.2 20.8 1.2 6.0%
CoV-OC43 16.1 1.0 16.4 1.3 16.4 1.0 16.3 1.1 6.9%
hMPV 17.4 1.3 17.5 1.4 17.9 1.0 17.7 1.3 7.2%
HRV/EV 16.5 0.7 16.7 1.1 16.7 0.8 16.7 0.9 5.3%
FluA-H1-2 19.3 1.1 19.5 1.2 19.9 0.8 19.7 1.1 5.5%
FluA-H1-2009 18.8 0.8 18.7 1.3 18.8 0.8 18.8 1.0 5.3%
FluA-H3 15.7 0.4 15.5 0.7 15.5 0.6 15.5 0.6 3.8%
FluA-pan1 15.2 0.5 15.5 0.7 15.3 0.6 15.4 0.6 3.8%
FluA-pan2 16.5 1.1 16.7 1.0 17.0 0.8 16.8 1.0 5.9%
FluB 15.6 0.5 15.4 0.6 15.6 0.5 15.5 0.5 3.3%
MERS1 19.5 1.1 19.8 1.3 19.8 0.9 19.9 1.1 5.3%
MERS2 17.5 0.9 17.9 1.1 17.6 0.9 17.8 1.0 5.4%
Mpne 16.1 0.9 16.0 1.0 16.0 0.9 16.0 0.9 5.7%
PIV1 15.8 1.4 15.7 1.4 16.0 1.5 15.8 1.4 9.1%
PIV2 18.4 1.2 18.0 1.2 18.3 1.1 18.2 1.2 6.5%
PIV3 17.3 0.7 17.2 0.8 17.3 0.6 17.3 0.7 4.2%
PIV4 18.1 0.7 17.9 0.8 17.9 0.6 17.9 0.7 3.9%
RSV 15.4 0.6 15.3 0.7 15.5 0.5 15.5 0.6 3.9%
Bper 18.8 0.6 19.2 0.3 19.2 0.3 19.2 0.4 7.0%
Cpne 16.0 1.8 15.6 1.9 15.9 1.9 15.7 1.9 8.4%
Mpne 19.0 1.4 19.2 1.2 18.9 1.4 18.9 1.3 8.8%
There appears to be no significant differences in mean Cp value when testing different
control lots on different days. Precision studies are acceptable.
c. Within-run Testing:
Within-run reproducibility was demonstrated in a separate study conducted by one
operator testing one lots of FilmArray RP2/RP2plus with one lot of FilmArray RP2
pouches on the FilmArray 2.0, each within one day. The results are shown in the tables
below:
8

[Table 1 on page 8]
Crossing Point (Cp) data for FilmArray RP2/RP2plus Control Panel Internal Precision Study									
									
Respiratory
Pathogen
Analyte	C11MAY17		G12JUN17		B21JUN17		All Lots	All Lots	All Lots
	Mean
Cp	SD	Mean
Cp	SD	Mean
Cp	SD	Mean Cp	SD	%CV
Adeno2	19.0	1.4	19.2	1.2	18.9	1.4	18.9	1.3	7.0%
Adeno3	17.1	1.5	17.6	1.5	17.6	1.3	17.5	1.5	8.4%
Adeno6	15.1	1.3	15.4	1.4	15.5	1.2	15.4	1.4	8.8%
Adeno7.1	15.5	1.3	15.5	1.3	16.0	1.1	15.7	1.3	8.3%
Adeno8	13.5	0.8	13.7	1.1	14.1	0.8	13.8	0.9	6.7%
IS1001	18.1	1.0	18.3	1.0	18.2	1.0	18.2	1.0	5.5%
ptxP	14.5	1.1	15.0	1.1	15.0	1.0	14.9	1.1	7.5%
Cpne	15.3	0.5	15.4	0.6	15.2	0.5	15.3	0.5	3.4%
CoV-229E	16.3	0.8	16.7	1.0	16.5	0.7	16.6	0.8	5.1%
CoV-HKU1	17.5	0.6	17.5	0.8	17.7	0.6	17.6	0.7	3.9%
CoV-NL63	17.0	0.9	17.1	1.0	17.2	0.8	17.1	0.9	5.1%
CoV-OC43-2	20.3	1.5	20.5	1.4	20.9	1.2	20.8	1.2	6.0%
CoV-OC43	16.1	1.0	16.4	1.3	16.4	1.0	16.3	1.1	6.9%
hMPV	17.4	1.3	17.5	1.4	17.9	1.0	17.7	1.3	7.2%
HRV/EV	16.5	0.7	16.7	1.1	16.7	0.8	16.7	0.9	5.3%
FluA-H1-2	19.3	1.1	19.5	1.2	19.9	0.8	19.7	1.1	5.5%
FluA-H1-2009	18.8	0.8	18.7	1.3	18.8	0.8	18.8	1.0	5.3%
FluA-H3	15.7	0.4	15.5	0.7	15.5	0.6	15.5	0.6	3.8%
FluA-pan1	15.2	0.5	15.5	0.7	15.3	0.6	15.4	0.6	3.8%
FluA-pan2	16.5	1.1	16.7	1.0	17.0	0.8	16.8	1.0	5.9%
FluB	15.6	0.5	15.4	0.6	15.6	0.5	15.5	0.5	3.3%
MERS1	19.5	1.1	19.8	1.3	19.8	0.9	19.9	1.1	5.3%
MERS2	17.5	0.9	17.9	1.1	17.6	0.9	17.8	1.0	5.4%
Mpne	16.1	0.9	16.0	1.0	16.0	0.9	16.0	0.9	5.7%
PIV1	15.8	1.4	15.7	1.4	16.0	1.5	15.8	1.4	9.1%
PIV2	18.4	1.2	18.0	1.2	18.3	1.1	18.2	1.2	6.5%
PIV3	17.3	0.7	17.2	0.8	17.3	0.6	17.3	0.7	4.2%
PIV4	18.1	0.7	17.9	0.8	17.9	0.6	17.9	0.7	3.9%
RSV	15.4	0.6	15.3	0.7	15.5	0.5	15.5	0.6	3.9%
Bper	18.8	0.6	19.2	0.3	19.2	0.3	19.2	0.4	7.0%
Cpne	16.0	1.8	15.6	1.9	15.9	1.9	15.7	1.9	8.4%
Mpne	19.0	1.4	19.2	1.2	18.9	1.4	18.9	1.3	8.8%

--- Page 9 ---
FilmArray RP2/RP2plus Control Panel Summary of Within-run Reproducibility Results
No. of Pouch Correct
Control Control Lot#
Tests Lot Results
FilmArray RP2/RP2plus Positive Control G12JUN17A 6 606817 6/6 (100%)
FilmArray RP2/RP2plus Negative Control F12JUN17A 6 606817 6/6 (100%)
Crossing Point (Cp) data for FilmArray RP2/RP2plus Control Panel Within-run
Reproducibility
FilmArray RP2/RP2plus Positive (Lot G12JUN17A)
Respiratory Pathogen
Mean Cp SD
Analyte
Adeno2 19.4 1.5
Adeno3 16.5 1.2
Adeno6 14.1 1.1
Adeno7.1 14.4 1.2
Adeno8 13.1 0.9
IS1001 17.7 0.9
ptxP 14.2 0.8
Cpne 15.3 0.5
CoV-229E 16.7 0.7
CoV-HKU1 17.3 0.8
CoV-NL63 16.4 0.9
CoV-OC43-2 20.0 1.8
CoV-OC43 16.1 0.5
hMPV 16.6 1.3
HRV/EV 16.4 0.7
FluA-H1-2 18.7 1.1
FluA-H1-2009 18.4 1.2
FluA-H3 15.4 0.6
FluA-pan1 15.5 0.5
FluA-pan2 15.8 0.8
FluB 15.1 0.4
MERS1 19.4 1.4
MERS2 17.8 1.1
Mpne 15.2 0.8
PIV1 14.5 1.2
PIV2 16.9 0.9
PIV3 16.9 0.7
PIV4 17.6 0.9
9

[Table 1 on page 9]
FilmArray RP2/RP2plus Control Panel Summary of Within-run Reproducibility Results				
				
Control	Control Lot#	No. of
Tests	Pouch
Lot	Correct
Results
FilmArray RP2/RP2plus Positive Control	G12JUN17A	6	606817	6/6 (100%)
FilmArray RP2/RP2plus Negative Control	F12JUN17A	6	606817	6/6 (100%)

[Table 2 on page 9]
Crossing Point (Cp) data for FilmArray RP2/RP2plus Control Panel Within-run		
Reproducibility		
Respiratory Pathogen
Analyte	FilmArray RP2/RP2plus Positive (Lot G12JUN17A)	
	Mean Cp	SD
Adeno2	19.4	1.5
Adeno3	16.5	1.2
Adeno6	14.1	1.1
Adeno7.1	14.4	1.2
Adeno8	13.1	0.9
IS1001	17.7	0.9
ptxP	14.2	0.8
Cpne	15.3	0.5
CoV-229E	16.7	0.7
CoV-HKU1	17.3	0.8
CoV-NL63	16.4	0.9
CoV-OC43-2	20.0	1.8
CoV-OC43	16.1	0.5
hMPV	16.6	1.3
HRV/EV	16.4	0.7
FluA-H1-2	18.7	1.1
FluA-H1-2009	18.4	1.2
FluA-H3	15.4	0.6
FluA-pan1	15.5	0.5
FluA-pan2	15.8	0.8
FluB	15.1	0.4
MERS1	19.4	1.4
MERS2	17.8	1.1
Mpne	15.2	0.8
PIV1	14.5	1.2
PIV2	16.9	0.9
PIV3	16.9	0.7
PIV4	17.6	0.9

--- Page 10 ---
Within-run reproducibility studies for the FilmArray RP2/RP2plus Control Panel are
acceptable.
d. Lot-to-Lot Testing:
Lot-to-lot reproducibility was demonstrated by testing three lots of FilmArray
RP2/RP2plus Positive Control using the same pouch lot. Results are shown in the
following tables.
FilmArray RP2/RP2plus Control Panel Summary of Lot-to-Lot Reproducibility Results
Control Lot # Number of Tests Pouch Lot Correct Results
C11MAY17A 5 455917 5/5 (100%)
G12JUN17A 5 455917 5/5 (100%)
B21JUN17A 5 455917 5/5 (100%)
Crossing Point (Cp) data for FilmArray RP2/RP2plus Control Panel Lot-to-Lot
Reproducibility
Respiratory C11MAY17A G12JUN17A B21JUN17A All lots All Lots
Pathogen Analyte Mean Cp Mean Cp Mean Cp Mean Cp SD
Adeno2 18.3 18.7 18.7 18.6 0.2
Adeno3 18.0 17.8 18.0 17.9 0.1
Adeno6 16.0 15.7 16.1 16.0 0.2
Adeno7.1 16.4 16.2 17.0 16.5 0.4
Adeno8 13.7 13.7 14.2 13.8 0.3
IS1001 18.4 18.2 18.2 18.3 0.1
ptxP 14.9 14.9 15.0 14.9 0.1
Cpne 15.3 15.2 15.2 15.2 0.0
CoV-229E 16.0 16.2 16.1 16.1 0.1
CoV-HKU1 17.4 17.2 17.5 17.4 0.2
CoV-NL63 17.6 17.4 17.7 17.5 0.1
CoV-OC43-2 21.0 20.7 21.4 21.0 0.3
CoV-OC43 15.5 15.5 15.8 15.6 0.2
hMPV 18.1 17.8 18.6 18.1 0.4
HRV/EV 16.2 16.1 16.2 16.2 0.1
FluA-H1-2 19.8 19.7 20.2 19.9 0.3
FluA-H1-2009 18.3 18.1 18.4 18.3 0.2
FluA-H3 15.4 15.2 15.3 15.3 0.1
FluA-pan1 15.1 15.1 15.1 15.1 0.0
FluA-pan2 17.3 17.1 17.6 17.3 0.2
10

[Table 1 on page 10]
FilmArray RP2/RP2plus Control Panel Summary of Lot-to-Lot Reproducibility Results			
Control Lot #	Number of Tests	Pouch Lot	Correct Results
C11MAY17A	5	455917	5/5 (100%)
G12JUN17A	5	455917	5/5 (100%)
B21JUN17A	5	455917	5/5 (100%)

[Table 2 on page 10]
Crossing Point (Cp) data for FilmArray RP2/RP2plus Control Panel Lot-to-Lot					
Reproducibility					
Respiratory
Pathogen Analyte	C11MAY17A	G12JUN17A	B21JUN17A	All lots	All Lots
	Mean Cp	Mean Cp	Mean Cp	Mean Cp	SD
Adeno2	18.3	18.7	18.7	18.6	0.2
Adeno3	18.0	17.8	18.0	17.9	0.1
Adeno6	16.0	15.7	16.1	16.0	0.2
Adeno7.1	16.4	16.2	17.0	16.5	0.4
Adeno8	13.7	13.7	14.2	13.8	0.3
IS1001	18.4	18.2	18.2	18.3	0.1
ptxP	14.9	14.9	15.0	14.9	0.1
Cpne	15.3	15.2	15.2	15.2	0.0
CoV-229E	16.0	16.2	16.1	16.1	0.1
CoV-HKU1	17.4	17.2	17.5	17.4	0.2
CoV-NL63	17.6	17.4	17.7	17.5	0.1
CoV-OC43-2	21.0	20.7	21.4	21.0	0.3
CoV-OC43	15.5	15.5	15.8	15.6	0.2
hMPV	18.1	17.8	18.6	18.1	0.4
HRV/EV	16.2	16.1	16.2	16.2	0.1
FluA-H1-2	19.8	19.7	20.2	19.9	0.3
FluA-H1-2009	18.3	18.1	18.4	18.3	0.2
FluA-H3	15.4	15.2	15.3	15.3	0.1
FluA-pan1	15.1	15.1	15.1	15.1	0.0
FluA-pan2	17.3	17.1	17.6	17.3	0.2

--- Page 11 ---
FluB 15.7 15.5 15.7 15.6 0.1
MERS1 19.8 19.7 20.0 19.8 0.2
MERS2 17.5 17.4 17.5 17.5 0.1
Mpne 16.8 16.7 16.9 16.8 0.1
PIV1 17.1 16.9 17.8 17.3 0.4
PIV2 19.4 19.0 19.5 19.3 0.3
PIV3 17.2 17.0 17.3 17.2 0.2
PIV4 17.9 17.9 18.0 17.9 0.1
RSV 15.5 15.2 15.6 15.4 0.2
Lot-to-Lot reproducibility studies for the FilmArray RP2/RP2plus Control Panel are
acceptable.
e. Linearity/assay reportable range:
Not applicable
f. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
Not applicable
Stability:
Open Vial Stability: Not applicable because FilmArray RP2/RP2plus Control Panel is
packaged for single use.
Closed Vial Real-time Stability: An accelerated stability study was performed to
establish the shelf life stability claims for FilmArray RP2/RP2plus Control Panel.
Based on this study, the FilmArray RP2/RP2plus Control Panel is expected to be
stable until the expiration date (12 months) when stored frozen (– 20°C or colder) and
unopened. This product is for single use.
Real-Time Stability Program: Real-time stability studies are ongoing to support
product claims and to monitor potential assay modifications for which the FilmArray
RP2/RP2plus Control Panel is indicated for use. Real-time stability study protocols
and acceptance criteria were reviewed and found to be acceptable.
Shipping Stability: MMQCI ships the FilmArray RP2/RP2plus Control Panel on dry
ice with overnight delivery, ensuring that the control material remains frozen upon
receipt. The frozen control material is then to be stored at -20oC, as indicated in the
FilmArray RP2/RP2plus Control Panel Package insert. A shipping study was
performed to confirm the shipping process and to investigate the outcome of a
11

[Table 1 on page 11]
FluB	15.7	15.5	15.7	15.6	0.1
MERS1	19.8	19.7	20.0	19.8	0.2
MERS2	17.5	17.4	17.5	17.5	0.1
Mpne	16.8	16.7	16.9	16.8	0.1
PIV1	17.1	16.9	17.8	17.3	0.4
PIV2	19.4	19.0	19.5	19.3	0.3
PIV3	17.2	17.0	17.3	17.2	0.2
PIV4	17.9	17.9	18.0	17.9	0.1
RSV	15.5	15.2	15.6	15.4	0.2

--- Page 12 ---
possible shipping delay and subsequent arrival with no dry ice. The study evaluated
two (2) lots of the FilmArray RP2/RP2plus Positive Control placed in dry ice and was
stored for two (2) days at ambient temperature then tested using the FilmArray
RP2plus Assay. To simulate a shipping delay, two (2) lots of the FilmArray
RP2/RP2plus Positive Control were stored for up to 5 days at ambient temperature
and tested using the FilmArray RP2plus Assay.
The study demonstrated that the FilmArray RP2/RP2plus Positive Control is stable
for two (2) days on dry ice in MMQCI’s standard shipping box. FilmArray
RP2/RP2plus Positive Control is stable after five (5) days at ambient temperatures of
approximately 19-21°C. The FilmArray RP2/RP2plus Positive Control should be
stored frozen (–20°C or colder) as indicated in the package insert.
Expected Values:
FilmArray RP2/RP2plus Control Panel is a qualitative control and the expected
results are listed in the tables below.
FilmArray RP2/RP2plus Positive Control FilmArray Result Summary
Viruses
Detected Adenovirus
Detected Coronavirus 229E
Detected Coronavirus HKU1
Detected Coronavirus NL63
Detected Coronavirus OC43
Detected Human Metapneumovirus
Detected Human Rhinovirus/ Enterovirus
Detected Influenza A H1-2009
Detected Influenza A H3
Detected Influenza B
Detected Middle East Respiratory Syndrome*
Detected Parainfluenza Virus 1
Detected Parainfluenza Virus 2
Detected Parainfluenza Virus 3
Detected Parainfluenza Virus 4
Detected Respiratory Syncytial Virus
Bacteria
Detected Bordetella parapertussis (IS1001)
Detected Bordetella pertussis (ptxP)
Detected Chlamydia pneumoniae
Detected Mycoplasma pneumoniae
* Middle East Respiratory Syndrome Coronavirus is reported on RP2plus only
12

[Table 1 on page 12]
FilmArray RP2/RP2plus Positive Control FilmArray Result Summary
Viruses
Detected Adenovirus
Detected Coronavirus 229E
Detected Coronavirus HKU1
Detected Coronavirus NL63
Detected Coronavirus OC43
Detected Human Metapneumovirus
Detected Human Rhinovirus/ Enterovirus
Detected Influenza A H1-2009
Detected Influenza A H3
Detected Influenza B
Detected Middle East Respiratory Syndrome*
Detected Parainfluenza Virus 1
Detected Parainfluenza Virus 2
Detected Parainfluenza Virus 3
Detected Parainfluenza Virus 4
Detected Respiratory Syncytial Virus
Bacteria
Detected Bordetella parapertussis (IS1001)
Detected Bordetella pertussis (ptxP)
Detected Chlamydia pneumoniae
Detected Mycoplasma pneumoniae

--- Page 13 ---
FilmArray RP2/RP2plus Negative Control FilmArray Result Summary
Viruses
Not Detected Adenovirus
Not Detected Coronavirus 229E
Not Detected Coronavirus HKU1
Not Detected Coronavirus NL63
Not Detected Coronavirus OC43
Not Detected Human Metapneumovirus
Not Detected Human Rhinovirus/ Enterovirus
Not Detected Influenza A H1-2009
Not Detected Influenza A H3
Not Detected Influenza B
Not Detected Middle East Respiratory Syndrome*
Not Detected Parainfluenza Virus 1
Not Detected Parainfluenza Virus 2
Not Detected Parainfluenza Virus 3
Not Detected Parainfluenza Virus 4
Not Detected Respiratory Syncytial Virus
Bacteria
Not Detected Bordetella parapertussis (IS1001)
Not Detected Bordetella pertussis (ptxP)
Not Detected Chlamydia pneumoniae
Not Detected Mycoplasma pneumoniae
* Middle East Respiratory Syndrome Coronavirus is reported on RP2plus only
Matrix Effects:
A study was performed to evaluate the effect of the FilmArray RP2/RP2plus Control
Panel in the presence of viral transport media (VTM). Equal volumes of the same
concentration of inactivated Influenza A H1N1-2009 were spiked into 370μL of VTM
as well as 370μL of FilmArray RP2/RP2plus Negative Control, which contains the
identical matrix found in the FilmArray RP2/RP2plus Positive Control. Both sample
types of the H1N1-2009 were tested in triplicate by the FilmArray RP2plus assay.
Results demonstrated that samples prepared with FilmArray RP2/RP2plus Control
Panel matrix generate equivalent results to samples prepared with VTM. Study results
are shown in the table below:
13

[Table 1 on page 13]
FilmArray RP2/RP2plus Negative Control FilmArray Result Summary
Viruses
Not Detected Adenovirus
Not Detected Coronavirus 229E
Not Detected Coronavirus HKU1
Not Detected Coronavirus NL63
Not Detected Coronavirus OC43
Not Detected Human Metapneumovirus
Not Detected Human Rhinovirus/ Enterovirus
Not Detected Influenza A H1-2009
Not Detected Influenza A H3
Not Detected Influenza B
Not Detected Middle East Respiratory Syndrome*
Not Detected Parainfluenza Virus 1
Not Detected Parainfluenza Virus 2
Not Detected Parainfluenza Virus 3
Not Detected Parainfluenza Virus 4
Not Detected Respiratory Syncytial Virus
Bacteria
Not Detected Bordetella parapertussis (IS1001)
Not Detected Bordetella pertussis (ptxP)
Not Detected Chlamydia pneumoniae
Not Detected Mycoplasma pneumoniae

--- Page 14 ---
Respiratory Spiked BEI H1N1-2009 Crossing Point (Cp)
Pathogen
VTM Mean Cp MMQCI Matrix Mean Cp
Analyte
FluA-H1-2009 17.7 19.1 18.3 18.4 16.9 18.7 17.9 17.8
FluA-pan1 12.8 13.5 12.9 13.1 12.0 12.2 12.3 12.2
FluA-pan2 19.1 19.9 19.8 19.6 19.0 19.3 19.7 19.3
g. Detection limit:
Not applicable
h. Analytical Reactivity (Inclusivity):
Not applicable
i. Cross Reactivity:
Not applicable
j. Interference:
Not applicable
k. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Not applicable.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
14

[Table 1 on page 14]
Respiratory
Pathogen
Analyte	Spiked BEI H1N1-2009 Crossing Point (Cp)							
	VTM			Mean Cp	MMQCI Matrix			Mean Cp
								
FluA-H1-2009	17.7	19.1	18.3	18.4	16.9	18.7	17.9	17.8
FluA-pan1	12.8	13.5	12.9	13.1	12.0	12.2	12.3	12.2
FluA-pan2	19.1	19.9	19.8	19.6	19.0	19.3	19.7	19.3

--- Page 15 ---
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not Applicable.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809 and
the specials controls for this device type.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
15